- Home
- YGMZ vs CUE Comparison
YGMZ vs CUE Comparison
Compare YGMZ & CUE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YGMZ
- CUE
- Stock Information
- Founded
- YGMZ 2002
- CUE 2014
- Country
- YGMZ China
- CUE United States
- Employees
- YGMZ N/A
- CUE N/A
- Industry
- YGMZ Transportation Services
- CUE Biotechnology: Pharmaceutical Preparations
- Sector
- YGMZ Consumer Discretionary
- CUE Health Care
- Exchange
- YGMZ Nasdaq
- CUE Nasdaq
- Market Cap
- YGMZ 72.3M
- CUE 59.5M
- IPO Year
- YGMZ 2020
- CUE 2018
- Fundamental
- Price
- YGMZ $0.89
- CUE $0.78
- Analyst Decision
- YGMZ
- CUE Strong Buy
- Analyst Count
- YGMZ 0
- CUE 2
- Target Price
- YGMZ N/A
- CUE $3.00
- AVG Volume (30 Days)
- YGMZ 32.5K
- CUE 108.9K
- Earning Date
- YGMZ 01-01-0001
- CUE 08-12-2025
- Dividend Yield
- YGMZ N/A
- CUE N/A
- EPS Growth
- YGMZ N/A
- CUE N/A
- EPS
- YGMZ N/A
- CUE N/A
- Revenue
- YGMZ $40,429,750.00
- CUE $8,286,000.00
- Revenue This Year
- YGMZ N/A
- CUE N/A
- Revenue Next Year
- YGMZ N/A
- CUE $10.19
- P/E Ratio
- YGMZ N/A
- CUE N/A
- Revenue Growth
- YGMZ N/A
- CUE N/A
- 52 Week Low
- YGMZ $0.63
- CUE $0.45
- 52 Week High
- YGMZ $1.77
- CUE $1.99
- Technical
- Relative Strength Index (RSI)
- YGMZ 51.72
- CUE 44.82
- Support Level
- YGMZ $0.75
- CUE $0.77
- Resistance Level
- YGMZ $1.06
- CUE $0.89
- Average True Range (ATR)
- YGMZ 0.15
- CUE 0.04
- MACD
- YGMZ 0.03
- CUE -0.01
- Stochastic Oscillator
- YGMZ 61.44
- CUE 5.98
About YGMZ MingZhu Logistics Holdings Limited
MingZhu Logistics Holdings Ltd is a Holding company. Its business activities include trucking services and car owner services. The segments of the company are the trucking business, car owner services business, and liquor distribution business.
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.